Validating the HUGO™-Tau Mouse: A New Path for Alzheimer's & FTD Drug Discovery скачать в хорошем качестве

Validating the HUGO™-Tau Mouse: A New Path for Alzheimer's & FTD Drug Discovery

Discover how Cyagen's HUGO-Tau mouse models are a game-changer for Alzheimer's and neurodegenerative disease research. Join us for an in-depth exploration of a groundbreaking nine-month study validating Cyagen's fully humanized HUGO-Tau knock-in mouse models. We'll show you how these advanced models (wild-type, P301L, and P301S mutations) successfully replicate the complex progression of human tauopathies like Alzheimer's Disease (AD) and Frontotemporal Dementia (FTD). This video uncovers key findings from our comprehensive preclinical validation experiments: 🔹 Behavioral Analysis: See how cognitive deficits, measured through tests like Novel Object Recognition, appear at different stages in the mutant lines, mirroring human disease progression. 🔹 Pathological Evidence: We provide clear evidence of Tau pathology through immunohistochemistry (IHC) and Western Blot, showing the formation of hyperphosphorylated Tau and neurofibrillary tangles in the hippocampus. 🔹 The Power of Humanization: Understand why the wild-type humanized Tau model serves as an ideal control and why this entire series is a robust tool for developing next-generation AD therapeutics and non-invasive early diagnostic methods like peripheral blood biomarker tests. 💜 This World Alzheimer's Month, as we unite in the fight for a cure, we are highlighting a groundbreaking study that offers new hope.  ▶ This study confirms the HUGO-Tau series as a reliable and predictive platform for accelerating the fight against neurodegenerative diseases. Learn more about Cyagen's neurodegenerative disease models: https://www.cyagen.com/cro-services/n... Timestamps:  0:00 - Introduction: The 9-Month Tau Experiment 1:16 - Experimental Design: Models, Timelines, and Tests 2:20 - Behavioral Results: 3-Month Baseline 3:08 - Behavioral Results: Cognitive Deficits Emerge at 6 Months 4:53 - Behavioral Results: Disease Progression at 9 Months 5:23 - The Importance of the Wild-Type HUGO-Tau Control 6:33 - Pathological Study Design: Staining and Western Blot 7:50 - Pathology Results: Human Tau Expression (HT7 Staining) 9:57 - Pathology Results: Pathological Tau Formation (AT8 Staining) 11:10 - The Broader Impact: Therapeutics and Diagnostics